… Apixaban is a selective … apixaban to be noninferior to vitamin K antagonists in the prevention
of stroke and VTE, with a good safety profile. This article aims to review the use of apixaban …

… Apixaban is considered the DOAC of choice by the HSE Medicines Management … There is
no longer a requirement to make an online application for reimbursement of apixaban. There …

… Both studies utilized pooled normal plasma spiked with apixaban. In the current study, we
used plasma samples from 10 healthy individuals spiked with pure apixaban to investigate the …

… Apixaban inhibits free and clot-bound factor Xa and prothrombinase activity. Apixaban has
… Apixaban and rivaroxaban calibrators are commercially available for this purpose. However…

… Apixaban should be used with caution in all of the special populations and avoided in those
with severe renal and hepatic impairment. A 50% dose reduction should be considered in …

… apixaban concentration were chosen to assess the degree of effect brought about by apixaban
… chosen in subjects treated with apixaban was 200 ng/mL apixaban. Although no precise …

… All PT and APTT reagents demonstrated a higher sensitivity for edoxaban and rivaroxaban
than for apixaban. Anti-Xa methods were able to detect low concentrations of DOAC. DOACs …

… [3,7,11] Rates of GI bleeding associated with 110 mg dabigatran and apixaban were similar
to those in the warfarin arms of their trials. Dabigatran should also be avoided in patients …

… Most patients received apixaban or an apixaban placebo at a dose of 5 mg twice a day. A
total of 6% of the patients in the apixaban group and 7% in the aspirin group received 2.5 mg …

… Patients were randomly assigned in a double-blind, double-dummy design to receive
apixaban at a dose of 5 mg twice daily (2.5 mg twice daily when indicated) or aspirin at a dose of …